StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd (TEVA) stock

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30127% above fair value
$42.62+0.05 (+0.12%)

Close on Nov 17, 2026Market cap $49.66BP/E 71.0Yield –

Teva Pharmaceutical Industries operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Teva Pharmaceutical Industries's operating income for the twelve months ending Jun 30, 2026 was $1.60B, up 79.3% year over year. For fiscal 2025 it was $2.16B. Over ten years it grew -4.3% a year on average. The highest annual figure on record is $3.95B in fiscal 2014.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.16B–
FY2024Dec 31, 2024-$303.00M-170.0%
FY2023Dec 31, 2023$433.00M–
FY2022Dec 31, 2022-$2.20B-228.0%
FY2021Dec 31, 2021$1.72B–
FY2020Dec 31, 2020-$3.57B–
FY2019Dec 31, 2019-$443.00M–
FY2018Dec 31, 2018-$1.64B–
FY2017Dec 31, 2017-$17.48B-911.7%
FY2016Dec 31, 2016$2.15B-35.7%
FY2015Dec 31, 2015$3.35B-15.2%
FY2014Dec 31, 2014$3.95B+139.6%
FY2013Dec 31, 2013$1.65B-25.2%
FY2012Dec 31, 2012$2.21B-29.1%
FY2011Dec 31, 2011$3.11B-19.7%
FY2010Dec 31, 2010$3.87B+61.0%
FY2009Dec 31, 2009$2.41B+110.0%
FY2008Dec 31, 2008$1.15B-52.2%
FY2007Dec 31, 2007$2.40B–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$231.00M-150.8%
Q1 FY2026Mar 31, 2026$652.00M+25.6%
Q4 FY2025Dec 31, 2025$300.00M–
Q3 FY2025Sep 30, 2025$882.00M–
Q2 FY2025Jun 30, 2025$455.00M–
Q1 FY2025Mar 31, 2025$519.00M–
Q4 FY2024Dec 31, 2024-$29.00M-103.8%
Q3 FY2024Sep 30, 2024-$51.00M-114.8%
Q2 FY2024Jun 30, 2024-$5.00M–
Q1 FY2024Mar 31, 2024-$218.00M–
Q4 FY2023Dec 31, 2023$756.00M–
Q3 FY2023Sep 30, 2023$344.00M-18.9%
Q2 FY2023Jun 30, 2023-$654.00M–
Q1 FY2023Mar 31, 2023-$13.00M–
Q4 FY2022Dec 31, 2022-$940.00M-1305.1%
Q3 FY2022Sep 30, 2022$424.00M-31.9%
Q2 FY2022Jun 30, 2022-$967.00M-266.2%
Q1 FY2022Mar 31, 2022-$713.00M-264.3%
Q4 FY2021Dec 31, 2021$78.00M-80.8%
Q3 FY2021Sep 30, 2021$623.00M–
Q2 FY2021Jun 30, 2021$582.00M+236.4%
Q1 FY2021Mar 31, 2021$434.00M+127.2%
Q4 FY2020Dec 31, 2020$406.00M+174.3%
Q3 FY2020Sep 30, 2020-$4.34B–
Q2 FY2020Jun 30, 2020$173.00M–
Q1 FY2020Mar 31, 2020$191.00M+42.5%
Q4 FY2019Dec 31, 2019$148.00M–
Q3 FY2019Sep 30, 2019-$81.00M-606.3%
Q2 FY2019Jun 30, 2019-$644.00M–
Q1 FY2019Mar 31, 2019$134.00M-91.2%
Q4 FY2018Dec 31, 2018-$3.16B–
Q3 FY2018Sep 30, 2018$16.00M-95.8%
Q2 FY2018Jun 30, 2018-$14.00M–
Q1 FY2018Mar 31, 2018$1.53B+70.4%
Q4 FY2017Dec 31, 2017-$13.02B–
Q3 FY2017Sep 30, 2017$378.00M-50.6%
Q2 FY2017Jun 30, 2017-$5.74B–
Q1 FY2017Mar 31, 2017$895.00M–
Q4 FY2016Dec 31, 2016-$137.00M–
Q3 FY2016Sep 30, 2016$765.00M–

More Teva Pharmaceutical Industries figures

See a number that looks wrong?